On this page
Short answer Pregnancy and deucravacitinib: what to know Common questions Related questions Sources**Deucravacitinib (brand name Sotyktu) is generally not recommended during pregnancy, because there is not enough human safety information and animal studies showed harm to the fetus at high doses.**
Deucravacitinib is a TYK2 inhibitor taken by mouth for moderate to severe plaque psoriasis, and the FDA label reports no adequate human data on birth defects or miscarriage. Many people find their psoriasis calms down during pregnancy, so a planned pause is often reasonable. Treatments with a longer safety track record in pregnancy include moisturizers, topical corticosteroids used as directed, and narrowband UVB phototherapy. If you are already taking it and find out you are pregnant, keep your prenatal appointments and call your dermatologist rather than making a sudden change on your own. Planning ahead before conception gives you the most options.
Pregnancy and deucravacitinib: what to know
Common questions
Can you take Deucravacitinib while pregnant?
Deucravacitinib (Sotyktu) is a TYK2 inhibitor approved for plaque psoriasis, and the FDA label says there is not enough human data to judge risk in pregnancy. In animal studies, doses far above human exposure caused fetal harm, so clinicians usually stop it before conception or as soon as pregnancy is confirmed. Psoriasis often improves during pregnancy, and options with more safety experience exist, including moisturizers, topical corticosteroids used as directed, and narrowband UVB phototherapy. If you are pregnant or planning to be, talk with your dermatologist and your obstetric clinician before stopping or switching treatment.